Annex B: Early Medical Abortion at Home – Scottish Abortion Care Providers Guidelines
Guidelines for approval of early medical abortion with self-administration of mifepristone and misoprostol in the home setting – COVID-19
Early Medical Abortion at Home (EMAH)
The purpose of this document is to provide a guideline, in light of the current COVID-19 pandemic, for the provision of consultation via telemedicine and take-home mifepristone and misoprostol for early medical abortions. Where patients up to 11 weeks + 6 days gestation either choose or need (based on current public health advice) to self-administer, at home, rather than at a healthcare facility, or where clinics are not able to see women in person due to COVID-19-related staffing reasons and/or to minimise risk of transmission of covid-19.
If clinics are unable to or feel it would be inadvisable to see women in person due to restrictions and pressures as a result of COVID-19, the following protocol can be applied.
- After consultation by telephone and with verbal consent, the EMAH 'home' package (to be delivered at a defined time to a home address), should include mifepristone, misoprostol, pregnancy test and analgesia, with full written instructions and advice (or where patients are able to access these instructions from the service online, provide the website source), including emergency contact numbers.
- Providers should consider including antibiotics for chlamydia, and a supply of bridging contraception in the package where appropriate.
- The gestation limit should be taken by last menstrual period.
Evidence has clearly demonstrated that early medical abortion with at home self-administration of mifepristone and misoprostol is a safe method of abortion. There is no higher risk of complications than with medical abortions carried out as a day case in hospital.
This offers a choice to women requesting an abortion and, in addition to practical and logistical benefits and reduced risk to patients and staff of COVID-19 disease transmission and avoidance of delays to patient treatment, enables women to complete treatment in an environment where they feel most comfortable.Women meeting the inclusion criteria will be not be required to attend the clinic for mifepristone administration. They will self-administer both mifepristone and misoprostol at an agreed time interval between the two medications, thus completing treatment without the need for a face to face visit.
- Is certain of the decision to proceed to abortion and wishes to administer both first (mifepristone) and the second part of treatment (misoprostol) at home.
- Fulfils the criteria set out in the Abortion Act 1967.
- Is ordinarily resident in Scotland.
- Does not have symptoms of an ectopic pregnancy (pain/bleeding) or other indication for an ultrasound scan.
- Is ≤11+6 weeks gestation on the day of mifepristone administration (as calculated from the date of the last menstrual period).
- Is 16 years of age or above, unless appropriate supports are in place.
- Has no significant medical conditions or contraindications to medical abortion.
- Is able to understand all information given, and to follow instructions for mifepristone and misoprostol administration.
- Fully understands the need to confirm the success of the procedure in line with local protocols.
Contra-Indications / Caution for mifepristone / misoprostol
Mifepristone and misoprostol should be used with caution in certain conditions. Please refer to the table below:
- Inherited porphyria
- Chronic adrenal failure
- Known or suspected ectopic pregnancy
- Uncontrolled severe asthma
- Previous allergic reaction to one of drugs involved
Caution required in the following circumstances (discuss with senior medical staff)
- Woman on long-term corticosteroids
- Asthma (avoid if severe)
- Haemorrhagic disorder or on anticoagulant therapy
- Prosthetic heart valve or history of endocarditis
- Pre-existing heart disease
- Hepatic or renal impairment
- Severe anaemia
- Severe inflammatory bowel disease e.g. Crohn's
- IUCD in place (remove pre-procedure)
Day of telemedicine appointment
Appointment can be either by telephone or, where feasible, via video call.
1. Confirm that patient is certain of decision to proceed to abortion, including the self-administration of mifepristone and misoprostol at home. Obtain verbal consent in line with local policy.
2. Advise that the patient may wish to consider having an adult at home with them for support after they self-administer misoprostol. However, during the pandemic, and while public health advice does not permit mixing between households, this should only be if the adult lives in the same household as the patient.
3. Discuss contraception options and provide ongoing contraception in line with national guidelines.
4 If there are symptoms of significant anaemia, advise the patient she will need to have her full blood count (FBC) checked so will need to wait until she can have a clinic appointment at the earliest opportunity. If result confirms severe anaemia, arrange ward admission for misoprostol, and onward investigation and treatment as per local guidance.
5. No STI screening is required, but where the patient is at higher risk of STI, antibiotic treatment for chlamydia should be included in the pack with instructions about taking these.
6. Up to 10 weeks gestation, NICE guidance indicates that no anti-D is required for medical abortions. For those patients over 10 weeks, but under 11 + 6 weeks, whilst there is no strong evidence that anti-D is not necessary, there is also no evidence that it is needed. During the current period, the evidence suggests that the subsequent risks for rhesus negative patients of not receiving anti-D are likely to be very low and much smaller than the risk of exposure to and health impacts from covid-19 if the patient travels to clinic unnecessarily. On that basis, during the covid-19 outbreak only, no anti-D is required for these patients if they would not otherwise need to travel to a clinic.
7. Advise that the patient should administer 200 mg mifepristone orally. Advise the patient that if vomiting occurs within 2 hours then she should contact the clinic as mifepristone dose will need to be repeated.
8. Obtain home address where the take-home pack of mifepristone, misoprostol and analgesia can be delivered, in line with local policy and agree timing period for delivery. The patient should be advised on arrangements for delivery – the person leaving the package should leave it on the doorstep and will not need to take any signature, but will ring the door bell and want confirmation that the person is there to receive it (e.g. particularly if the person has or may have covid-19 they should not open the door while the delivery person is there, but could wave through the door or a window or answer a phone call to confirm that the package will be received by the correct person). The patient should also be advised to get in touch if they have not received the package within a few hours after the agreed time. While ideally providers should arrange delivery wherever possible, where this is not feasible, providers can use Royal Mail for delivery, but should ensure packages are sent special or recorded delivery.
9. Dispense prophylactic antibiotics for the at home package, if required, in line with local policy. The home package should also contain analgesia, bridging contraception if required and the pregnancy test to confirm success of the procedure.
10. Dispense take–home pack of mifepristone and misoprostol tablets. For patients at 10 weeks gestation or more, you should provide an additional dose of misoprostol to minimise the risk of an incomplete abortion. Traditional misoprostol administration has been by the vaginal route, but sublingual route and buccal routes are as effective. The patient should be advised on how to self-administer by the preferred route.a. Oral administration (swallowing) of misoprostol has lower efficacy. Oral administration should only be used if the pregnancy is < 7 weeks gestation and if vaginal, sublingual or buccal routes of administration of misoprostol are unacceptable to the patient.b. The patient should be made aware that administration by sublingual or buccal route is associated with higher likelihood of side effects. Misoprostol tablets administered buccally or sublingually should be placed in the mouth for 30 minutes, may not dissolve fully and are associated with an unpleasant taste in the mouth.
11. The patient should be advised that the standard dosing interval between mifepristone and misoprostol is 24-48 hrs, based upon efficacy. Misoprostol should thus normally be administered 24 to 48 hrs after mifepristone. Women who opt to administer misoprostol out with 24-48 hour period should be advised of the following:
a. Longer dosing interval (48 hrs up to 72 hrs) - There is evidence that the time interval between mifepristone and misoprostol can be prolonged up to 72 hrs, with similar efficacy, although the likelihood of bleeding prior to misoprostol is increased. The dosing interval should not be extended beyond 72 hours, without a further dose of mifepristone.
b. Shorter dosing interval (simultaneous administration up to 24 hours) – There is evidence of a greater failure rate and a delay in onset of bleeding with dose intervals of less than 24 hours.
c. Women should be advised that if no/minimal bleeding at 4 hours after misoprostol administration (or concern that the pregnancy has not been passed) that they should self-administer the additional dose of misoprostol provided according to instructions. For women over 10 weeks gestation, they may need to administer a third dose of misoprostol if there is still no bleeding within 4 hours of taking the second dose. If there is still no bleeding following the third dose, women should contact the clinic for advice.
12. Staff should complete EMAH paperwork, detailing patient understanding of treatment, the information that has been provided on what to expect at home (including information leaflet) and the 24 hour contact information for advice/concerns or emergency contact. Staff should also document when the patient will conduct the pregnancy test to confirm success of procedure.